- Home
- PMN vs PULM Comparison
PMN vs PULM Comparison
Compare PMN & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMN
- PULM
- Stock Information
- Founded
- PMN 2004
- PULM 2003
- Country
- PMN Canada
- PULM United States
- Employees
- PMN N/A
- PULM N/A
- Industry
- PMN Pharmaceuticals and Biotechnology
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- PMN Health Care
- PULM Health Care
- Exchange
- PMN Nasdaq
- PULM Nasdaq
- Market Cap
- PMN 22.3M
- PULM 18.3M
- IPO Year
- PMN N/A
- PULM N/A
- Fundamental
- Price
- PMN $0.56
- PULM N/A
- Analyst Decision
- PMN Strong Buy
- PULM
- Analyst Count
- PMN 3
- PULM 0
- Target Price
- PMN $4.33
- PULM N/A
- AVG Volume (30 Days)
- PMN 786.1K
- PULM 17.8K
- Earning Date
- PMN 11-13-2025
- PULM 11-07-2025
- Dividend Yield
- PMN N/A
- PULM N/A
- EPS Growth
- PMN N/A
- PULM N/A
- EPS
- PMN N/A
- PULM N/A
- Revenue
- PMN N/A
- PULM $369,000.00
- Revenue This Year
- PMN N/A
- PULM N/A
- Revenue Next Year
- PMN N/A
- PULM $134.88
- P/E Ratio
- PMN N/A
- PULM N/A
- Revenue Growth
- PMN N/A
- PULM N/A
- 52 Week Low
- PMN $0.38
- PULM $1.96
- 52 Week High
- PMN $1.59
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- PMN 63.37
- PULM 47.11
- Support Level
- PMN $0.39
- PULM $4.45
- Resistance Level
- PMN $0.61
- PULM $5.50
- Average True Range (ATR)
- PMN 0.04
- PULM 0.26
- MACD
- PMN 0.02
- PULM 0.02
- Stochastic Oscillator
- PMN 80.05
- PULM 38.53
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).